title: Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
abstract: To assess the effect of switching 1 eye to topical travoprost 0.004% preserved with SofZia (TRAVATAN Z solution) in patients who had chronic superficial punctate keratitis (SPK) in both eyes treated with benzalkonium chloride-preserved latanoprost 0.005% (XALATAN).
  
  
  
  This was a prospective, randomized, controlled, multicenter, open-label, comparative 3-month follow-up study. Patients with open-angle glaucoma or ocular hypertension who received XALATAN monotherapy for at least 3 months and had SPK in both eyes were enrolled at 9 facilities. For each patient, 1 eye was randomly selected and switched to TRAVATAN Z solution (T-group); the contralateral control eye was treated with XALATAN (X-group). SPK in 5 corneal regions, conjunctival hyperemia, tear breakup time (TBUT), and intraocular pressure (IOP) were examined in a masked manner at baseline, 1 month, and 3 months. Changes in SPK, hyperemia, TBUT, and IOP were compared within treatment groups and between treatment groups.
  
  
  
  Fifty-six patients completed the study. The frequency of SPK significantly decreased from baseline in the T-group and the X-group at 1 and 3 months (T-group, P<0.001; X-group, P<0.05). In the T-group, SPK scores were significantly improved in 4 corneal regions, excluding the superior region, at 1 and 3 months (all P<0.05), whereas in the X-group, SPK scores were significantly improved only in the temporal region at 1 month and in the inferior region at 3 months (P<0.05 for both). The total SPK score at 1 and 3 months in the T-group was significantly lower compared with the score in the X-group (P=0.0023 and 0.0102, respectively). The SPK score for the superior and central corneal region at 3 months in the T-group was significantly lower compared with the score in the X-group (P=0.0212 and 0.022, respectively). There were no substantial intergroup or intragroup differences in changes from baseline for hyperemia scores, TBUT, or IOP reduction.
  
  
  
  Switching therapy from benzalkonium chloride-preserved latanoprost to travoprost preserved with SofZia ameliorated chronic SPK. There were no clinically relevant changes in hyperemia, TBUT, or IOP.
authors.affiliation: *Department of Ophthalmology, University of Tokyo †Shirato Eye Clinic, Tokyo ‡Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto §Department of Ophthalmology, Ehime University, Ehime ∥Department of Ophthalmology, University of Ryukyus, Okinawa ¶Eguchi Eye Hospital, Hakodate #Department of Ophthalmology, Yokohama City University Medical Center, Yokohama **Yokohama Hodogaya Central Hospital, Yokohama, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Aihara
authors.forename: Yoko
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Shiro
authors.initials: S
authors.lastname: Mizoue
authors.forename: Yoshikuni
authors.initials: Y
authors.lastname: Arakaki
authors.forename: Naofumi
authors.initials: N
authors.lastname: Kita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage; D002908:Chronic Disease; D003315:Cornea / Q000000981:diagnostic imaging* / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D057915:Drug Substitution; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007634:Keratitis / Q000150:complications* / Q000175:diagnosis; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical / Q000008:administration & dosage; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D014065:Tonometry, Ocular; D000069557:Travoprost / Q000008:administration & dosage*
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D000069557:Travoprost